Lymphogram

Guerbet: 2023 Strategic Priorities

Retrieved on: 
Monday, January 16, 2023

Villepinte, 16 January 2023: Guerbet (FR0000032526 GBT), a global specialist in contrast agents and solutions for medical imaging has announced its strategic priorities for 2023 in a complex international environment characterised by persistent inflationary pressures and the revelation of new business opportunities for products listed in developing markets.

Key Points: 
  • Villepinte, 16 January 2023: Guerbet (FR0000032526 GBT), a global specialist in contrast agents and solutions for medical imaging has announced its strategic priorities for 2023 in a complex international environment characterised by persistent inflationary pressures and the revelation of new business opportunities for products listed in developing markets.
  • In Europe, the European Medicines Agency (EMA) review is expected in the second half of the year.
  • Guerbet also plans to divest the Occlugel technology acquired in 2018, including several ranges of microspheres for use in embolization.
  • Guerbet ultimately aims to enable the development of a major player in artificial intelligence applied to medical imaging in oncology.